On December IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, reported that the Company will host a conference call and live audio webcast on Saturday, December 11, 2021, at 7:30 p.m. EST (Press release, IGM Biosciences, DEC 6, 2021, https://investor.igmbio.com/news-releases/news-release-details/igm-biosciences-host-conference-call-and-webcast-review-igm-0 [SID1234596489]). The event will take place following an oral presentation featuring clinical data from the Phase 1 dose escalation study evaluating IGM-2323, the Company’s novel CD20 x CD3 T cell engager IgM antibody for the treatment of B cell proliferative diseases, at the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IGM’s management team will be joined by Elizabeth Budde, M.D., Ph.D., Assistant Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center.

The conference call may be accessed by dialing (866) 649-1996 (domestic) or (409) 217-8769 (international) and referring to conference ID 9695193. A live webcast of the presentation will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

On December 6, 2021 Redx Pharma (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, and Caris Life Sciences ("Caris"), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, reported that they have entered into a strategic partnership (Press release, Redx Pharma, DEC 6, 2021, View Source [SID1234596488]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The partnership will leverage Caris’ comprehensive Whole Transcriptome Sequencing (WTS) and Whole Exome Sequencing (WES) platform assay, real-world data and its Right-In-Time (RIT) clinical trial solutions to enhance the speed of U.S. accruals for Redx’s Phase 2 trial for the investigational Porcupine inhibitor, RXC004, in genetically-selected patients with Wnt-ligand dependent microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Utilizing Caris’ RIT clinical trial solution will help Redx match the right U.S. patients to the Phase 2 trial based on both the individual patient’s molecular tumour profile and the trial’s eligibility requirements, i.e., those whose cancers carry Ring Finger Protein 43 (RNF43) loss of function mutations or R-spondin (RSPO) fusions with MSS mCRC, and have progressed following therapy with current standard of care. Through the nationwide identification of eligible patients with the required genetic characteristics Caris’ flexible enrolment model will enable rapid initiation of study treatment for RXC004 at its extensive network of U.S. RIT trial sites, in addition to trial sites initiated by Redx.

Lisa Anson, Chief Executive Officer of Redx Pharma, said: "We are delighted to be partnering with Caris on several of their innovative technologies and approaches. Together we aim to greatly enhance the speed of our patient accrual for the U.S. into PORCUPINE, our RXC004 Phase 2 trial in patients with Wnt-ligand driven metastatic colorectal cancer who currently have few treatment options. The Caris approach will complement our screening capabilities, and potentially identify new populations where RXC004 may have utility."

"Unlike more limited panels, Caris tests all 22,000 genes in both DNA and RNA, which minimizes the potential of missing alterations that would inform drug development decisions," said Brian Lamon Ph.D., Chief Business Officer, Head of BioPharma Business Development at Caris Life Sciences. "We will comprehensively deploy all of our precision oncology tools to support and maximize the success of the RXC004 program."

The RXC004 Phase 2 trial in MSS mCRC patients (NCT04907539), known as the PORCUPINE trial, prospectively selects patients with Wnt-ligand dependence for treatment with Redx’s Porcupine inhibitor, RXC004. The study will recruit patients from the U.K., U.S., Spain and South Korea. The prevalence of the upstream Wnt pathway aberrations which drive Wnt-ligand dependence in MSS mCRC, RNF43 loss of function mutations and RSPO-fusions, is around 8%. As such, identification of potentially eligible MSS mCRC patients involves a significant screening effort. The International Coordinating Investigator in the U.S. for PORCUPINE, the RXC004 Phase 2 trial in colorectal cancer, is Professor Scott Kopetz at The University of Texas MD Anderson Cancer Center, Houston, TX.

The strategic partnership between Redx and Caris will also include a real-world evidence collaboration, using Caris’ extensive database of genetic aberrations, therapeutic interventions and patient outcomes, to understand the clinical outcomes for MSS CRC patients with these genetic aberrations. Utilizing Caris’ comprehensive data set will allow Redx to further characterize the target patient population, and potentially identify additional patient populations in MSS CRC where RXC004 may have efficacy. Financial terms have not been disclosed.

About RXC004
RXC004 is a wholly owned, potent, selective, oral, small-molecule inhibitor of the Porcupine enzyme, a key activator of Wnt ligands in the Wnt-signalling pathway. The Wnt pathway is well established as a driver of both tumour growth and immune evasion. Aberrant Wnt signalling contributes directly to tumour growth and plays an important role in immune evasion, which has also been linked to resistance to immune-checkpoint inhibitors (ICIs) such as nivolumab. By selecting patients with tumours that have high Wnt-ligand dependency, such as those with loss of function mutations in the RNF43 gene and fusions in the RSPO gene family, RXC004 has an opportunity to both directly inhibit the tumour growth and have an immune-enhancing effect to allow the patient’s immune system to better recognise and attack the tumour.

ICIs such as anti-PD-1 antibodies have revolutionised the treatment of cancer, but do not work in all patients. Wnt-pathway activation can enhance the ability of the tumour to evade destruction by the immune system and has been linked to lack of response to ICIs in these tumours. Redx scientists have observed in preclinical studies that RXC004 can block activation of the Wnt pathway and restore the ability of the immune system to fight the tumour. Thus, RXC004 offers potential to address some of the shortcomings of ICI therapies through increasing both response rates and duration of response, particularly in patient populations unresponsive to ICI therapy.

On December 6, 2021 ITI reported that it will be attending SITC (Free SITC Whitepaper) 2022 in Boston, MA (Press release, Immunomic Therapeutics, DEC 6, 2021, View Source [SID1234596487])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.

As the largest conference solely focused on cancer immunotherapy, the Annual Meeting & Pre-Conference Programs provides international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients.

December 6, 2021 MaaT Pharma S.A. ("MaaT Pharma" or the "Company"), a French clinical-stage biotech and a pioneer in the development of microbiome[1]-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, reported the partial exercise of the Over-Allotment Option in the context of the Company’s initial public offering on the regulated market of Euronext Paris (code ISIN : FR0012634822- ticker: MAAT) (Press release, MaaT Pharma, DEC 6, 2021, View Source [SID1234596486]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On December 3, 2021, Joint Global Coordinator and Joint Bookrunner, Portzamparc BNP Paribas, acting as stabilization agent, partially exercised the Over-Allotment Option resulting in the issuance of 314,055 additional new shares (out of a maximum of 349,999 shares) for a total amount of c. €4.2m, at the offering price of €13.50 per share.

As a result, the total number of MaaT Pharma shares offered in the context of the Company’s IPO amounts to 2,647,388 shares, thus increasing the size of the offering to c. €35.7m after the settlement-delivery of the additional new shares scheduled on December 7, 2021.

Following the settlement-delivery of the additional new shares, MaaT Pharma’s share capital will consist of 9,828,835 shares.

In addition, in accordance with the provisions of the Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and with Article 6 of the EU Delegated Regulation 2016/1052 of March 8, 2016, regarding conditions applicable to share buy-back programmes and stabilisation measures, Portzamparc BNP Paribas, acting as stabilization agent, declares having carried out the following stabilization operations on the Company’s shares:

The stabilization period began on November 8, 2021 and ended on December 3, 2021. The final stabilization operation was carried out on December 3, 2021. The stabilization transactions were carried out under the following conditions:

Trade date Intermediary Buy/Sell Daily total of shares Weighted average price (in EUR) Lowest / Highest price (in EUR) Aggregate amount (in EUR) Market
08/11/2021 Portzamparc Buy 6 453 13.5 13.5 87 115.50 Euronext Paris
09/11/2021 Portzamparc Buy 250 13.5 13.5 3 375.00 Euronext Paris
10/11/2021 Portzamparc Buy 820 13.5 13.5 11 070.00 Euronext Paris
11/11/2021 Portzamparc Buy 1 111 13.5 13.5 14 998.50 Euronext Paris
12/11/2021 Portzamparc Buy 2 520 13.5 13.5 34 020.00 Euronext Paris
15/11/2021 Portzamparc Buy 5 050 13.3812 13.3 / 13.5 67 575.06 Euronext Paris
16/11/2021 Portzamparc Buy 904 13.3272 13.2 / 13.5 12 047.79 Euronext Paris
17/11/2021 Portzamparc Buy 1 550 13.0388 12.6 / 13.5 20 210.14 Euronext Paris
18/11/2021 Portzamparc Buy 2 722 13.1242 12.7 /13.5 35 724.07 Euronext Paris
19/11/2021 Portzamparc Buy 295 13.4486 13.4 / 13.5 3 967.34 Euronext Paris
22/11/2021 Portzamparc Buy 0 – Euronext Paris
23/11/2021 Portzamparc Buy 208 13.3885 13.35 / 13.45 2 784.81 Euronext Paris
24/11/2021 Portzamparc Buy 90 13.3222 13.1 / 13.4 1 199.00 Euronext Paris
25/11/2021 Portzamparc Buy 340 13.2824 13.1 / 13.3 4 516.02 Euronext Paris
26/11/2021 Portzamparc Buy 582 12.9768 12.85 / 13.2 7 552.50 Euronext Paris
29/11/2021 Portzamparc Buy 725 12.413 12.3 / 12.8 8 999.43 Euronext Paris
30/11/2021 Portzamparc Buy 2381 11.9515 11.3 / 12.8 28 456.52 Euronext Paris
01/12/2021 Portzamparc Buy 513 12.9397 12.85 / 12.95 6 638.07 Euronext Paris
02/12/2021 Portzamparc Buy 200 12.77 12.6 / 13 2 554.00 Euronext Paris
03/12/2021 Portzamparc Buy 9230 13.2248 12.8 / 13.5 122 064.90 Euronext Paris

Share Ownership

Following the IPO and the partial exercise of the Over-Allotment Option, the share ownership and voting rights is as follows (to the Company’s best knowledge) :

After the exercise of the Over-Allotment Option
Shareholders Total number of shares % of share capital and voting rights
Hervé Affagard 133 848 1.36%
Total legal representatives 133 848 1.36%
Fonds Seventure 2 345 236 23.86%
Crédit Mutuel Innovation SAS 1 412 364 14.37%
Biocodex SAS 977 905 9.95%
Symbiosis LLC 2 027 702 20.63%
FPCI Fonds PSIM 1 177 439 11.98%
Other investors 368 883 3.75%
Total historical shareholders 8 309 529 84.54%
Employees and consultants 248 838 2.53%
Treasury shares 0 0.00%
Floating 1 136 620 11.56%
TOTAL 9 828 835 100.00%

Availability of the Prospectus

The Registration Document of the Company approved by the AMF on October 1, 2021, under the number I.21-057, the supplement of the Registration Document approved by the AMF on October 14, 2021, under the number I.21-061, the Security Notes and the summary of the Prospectus are available free of charge and on simple request from MaaT Pharma and on the following websites: amf-france.org and investir.maatpharma.com. The approval of the Prospectus should not be considered as an endorsement on the securities offered or admitted to trading on the regulated market of Euronext Paris.

[1] The microbiome (also called intestinal flora) refers to all the microorganisms (bacteria, archaea, yeasts, viruses, etc.) naturally present in the intestine. It plays a major role in the education and modulation of the immune system and in the metabolism.

On December 6, 2021 ITI reported that it will be virutally attending The 40th Annual Health Care Conference that will take place on January 10-13, 2022 at the Westin St. Francis in San Francisco, CA (Press release, Immunomic Therapeutics, DEC 6, 2021, View Source [SID1234596485]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.